

References for CEQUA® (cyclosporine ophthalmic solution) 0.09%

^a**Study design:** 1-week efficacy data come from a single-arm, open-label study evaluating 60 (46 assessable) patients at 7, 14, and 28 days. The primary endpoint was corneal higher-order aberrations. Exclusion criteria were similar to past studies with the exception that patients switching from another dry eye medication were not excluded.³

^b**Study design:** Real-world, retrospective, longitudinal cohort study utilizing data from the Symphony Health Integrated Dataverse (IDV), a national provider-based claims database, examining time to treatment discontinuation, probability of treatment discontinuation, and treatment persistence among patients with DED treated with CEQUA® (n=1846), Restasis® (n=2248), or Xiidra® (n=3008).⁵

References:

1. Goldberg DF, Malhotra RP, Schechter BA, Justice A, Weiss SL, Sheppard JD. A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease. *Ophthalmology*. 2019;126(9):1230-1237.
2. Malhotra R, Devries DK, Luchs J, et al. Effect of OTX-101, a novel nanomicellar formulation of cyclosporine A, on corneal staining in patients with keratoconjunctivitis sicca: A pooled analysis of phase 2b/3 and phase 3 studies. *Cornea*. 2019;38:1259-1265.
3. Cequa Onset of Action Trial (COAT) presented at: American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting; April 4-8, 2025; Los Angeles, CA.
4. Tauber J, Schechter BA, Bacharach J, et al. A phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease. *Clin Ophthalmol*. 2018;12:1921-1929.
5. Karpecki P, Barghout V, Schenkel B, et al. Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis. *BMC Ophthalmol*. 2023;23(1):443.
6. CEQUA prescribing information. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2022.

© 2025 Sun Pharmaceutical Industries, Inc. All rights reserved. CEQUA is a registered trademark of Sun Pharmaceutical Industries Limited. All other trademarks are the property of their respective owners.



PM-US-CQA-1953 07/2025